Search results
Results from the WOW.Com Content Network
Nucleoside analog reverse-transcriptase inhibitors (NARTIs or NRTIs) compose the first class of antiretroviral drugs developed. In order to be incorporated into the viral DNA, NRTIs must be activated in the cell by the addition of three phosphate groups to their deoxyribose moiety, to form NRTI triphosphates.
The first nucleoside reverse-transcriptase inhibitor with in vitro anti-HIV activity was zidovudine. [6] Since zidovudine was approved in 1987, six nucleosides and one nucleotide reverse-transcriptase inhibitor (NRTI) have been approved by FDA. [6]
There is a large family of nucleoside analogue reverse transcriptase inhibitors, because DNA production by reverse transcriptase is very different from normal human DNA replication, so it is possible to design nucleoside analogues that are preferentially incorporated by the former. Some nucleoside analogues, however, can function both as NRTIs ...
Pages in category "Nucleoside analog reverse transcriptase inhibitors" The following 21 pages are in this category, out of 21 total. This list may not reflect recent changes .
Nucleoside analog reverse transcriptase inhibitors (21 P) Pages in category "Reverse transcriptase inhibitors" The following 8 pages are in this category, out of 8 total.
Integrase inhibitor Remdesivir: COVID-19: viral RNA polymerase inhibitor Ribavirin: Hepatitis C [15] nucleoside analogue reverse transcriptase inhibitor: Rilpivirine (Edurant) [16] HIV Rimantadine: Influenza A: M2 proton channel antagonist Ritonavir: HIV HIV-1 protease inhibitor Saquinavir: HIV Simeprevir (Olysio) Hepatitis C Sofosbuvir ...
Nucleoside reverse-transcriptase inhibitors (NRTI) and nucleotide reverse-transcriptase inhibitors (NtRTI) are nucleoside and nucleotide analogues which inhibit reverse transcription. HIV is an RNA virus, so it can not be integrated into the DNA in the nucleus of the human cell unless it is first "reverse" transcribed into DNA.
Lamivudine is a nucleoside reverse transcriptase inhibitor and works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase. [1] Lamivudine was patented in 1995 and approved for use in the United States in 1995. [8] [9] It is on the World Health Organization's List of Essential Medicines. [10] It is available as a generic ...